Your browser doesn't support javascript.
loading
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.
Xu, Yan; Deng, Shuhui; Mao, Xuehan; An, Gang; Li, Zengjun; Wang, Yafei; Fulciniti, Mariateresa; Ho, Matthew; Lin, Jianhong; Sui, Weiwei; Liu, Wei; Zou, Dehui; Yi, Shuhua; Huang, Wenyang; Liu, Hong; Lv, Rui; Li, Jian; Wang, Tingyu; Du, Chenxing; Munshi, Nikhil C; Qiu, Lugui.
Afiliação
  • Xu Y; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China; Department of Medical Oncology, Jerome Lipper Center for Multiple Myeloma Research, Lebow Institute for Myeloma The
  • Deng S; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Mao X; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • An G; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Li Z; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Wang Y; Department of Hematology, Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
  • Fulciniti M; Department of Medical Oncology, Jerome Lipper Center for Multiple Myeloma Research, Lebow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Ho M; Department of Medical Oncology, Jerome Lipper Center for Multiple Myeloma Research, Lebow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Lin J; Department of Medical Oncology, Jerome Lipper Center for Multiple Myeloma Research, Lebow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Sui W; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Liu W; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Zou D; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Yi S; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Huang W; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Liu H; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Lv R; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Li J; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Wang T; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Du C; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China.
  • Munshi NC; Department of Medical Oncology, Jerome Lipper Center for Multiple Myeloma Research, Lebow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address: Nikhil_Munshi@dfci.harvard.edu.
  • Qiu L; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academic Medical Science and Peking Union Medical College, Tianjin, China. Electronic address: qiulg@ihcams.ac.cn.
Clin Lymphoma Myeloma Leuk ; 18(6): 422-430, 2018 06.
Article em En | MEDLINE | ID: mdl-29625927
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Doenças do Sistema Nervoso Periférico / Bortezomib / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Doenças do Sistema Nervoso Periférico / Bortezomib / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lymphoma Myeloma Leuk Ano de publicação: 2018 Tipo de documento: Article